Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for MP0712 (212Pb x DLL3) in Small cell lung cancer (SCLC). The expected timing is based on the latest available company guidance and may change.
Global partnership w/ Orano Med. 11/12/25– Presented data at TRP Summit Europe'25. IND filed; Ph1 trial initiation by YE 2025 with data in 2026. 02/02/26:- TWC 2026 imaging/dosimetry data reported; US Ph1/2a NCT07278479 ongoing; initial safety data in 2026. 03/12/26:- US Ph1/2a NCT07278479 recruiting; MP0712 initial clinical data expected in 2026; imaging/dosimetry supports study design. 05/12/26:- US Ph1/2a NCT07278479 recruiting at four sites; trial-in-progress posters planned for SNMMI 2026 and ASCO 2026. 05/30/26:- Trial-in-progress posters at ASCO/SNMMI 2026. Initial Phase 1/2a clinical data expected in 2026. 07/02/26:- First patients dosed; five US sites recruiting. Initial data expected in coming months 2026; comprehensive safety/efficacy data 2027. 07/06/26:- Ph1/2a dosing ongoing; initial data expected in coming months. Comprehensive safety/efficacy dataset expected in 2027.
Verification
Confirm timing and program details against the company announcement or filing.